Pak1, adjuvant tamoxifen therapy, and breast cancer recurrence risk in a Danish population-based study

BACKGROUND: Adjuvant tamoxifen therapy approximately halves the risk of estrogen receptor positive breast cancer recurrence, but many women do not respond to therapy. Observational studies nested in clinical trial populations suggest that overexpression or nuclear localization of p21-activated kinas...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Acta Oncol
Auteurs principaux: Ahern, Thomas P., Cronin-Fenton, Deirdre P., Lash, Timothy L., Sørensen, Henrik Toft, Ording, Anne Gulbech, Hamilton-Dutoit, Stephen J., Hellberg, Ylva
Format: Artigo
Langue:Inglês
Publié: 2016
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4943575/
https://ncbi.nlm.nih.gov/pubmed/27056567
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/0284186X.2016.1150606
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires